Brazil Patent Granted for Biocept's Target Selector™ Oncogene Mutation Enrichment and Detection Platform
"The issuance of this patent further expands
The recently issued Brazilian patent encompasses
"We are pleased to be granted this Brazilian patent covering our Switch-Blocker technology, which increases our total patent portfolio to 39 as we continue to expand our global intellectual property protection," stated
About
The "Switch-Blocker" technology covered by Brazilian Patent No. BR112013028296-7 further expands on South Korean Patent No. 2010601, Japanese Patent No 6404118, European Patent No. 2,705,162,
In clinical validation studies,
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, the utility and effectiveness of our intellectual property protections, our ability to expand the adoption of our tests globally, and the cost saving attributes of our switch-blocker technology, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Investor Contact:
LHA Investor Relations
Jcain@lhai.com
310-691-7100
Media Contact:
CORE IR
julesa@coreir.com
917-885-7378
View original content to download multimedia:http://www.prnewswire.com/news-releases/brazil-patent-granted-for-biocepts-target-selector-oncogene-mutation-enrichment-and-detection-platform-301038067.html
SOURCE